I see the future and the future is bright indeed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ISOLF
Check this out MADDSTACKER this was written up last night from Barchart Opinion. Here's the link https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
Isodiol International Inc. (ISOL.CN)
0.640 +0.110 (+20.75%) 11/17/17 [CNSX]
BARCHART OPINION for Fri, Nov 17th, 2017
Set Alerts Watchlist
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/ISOL.CN/opinion
Great news for $ISOLF this morning.
My 2 favorite companies currently are $IMLFF and $ISOLF over the long term.
I'm long term on $IMLFF also, 2 to 3 years and who knows the potential of this company.
$ISOLF News
Isodiol International Acquires Global Rights to produce products under an Innovative Delivery System Patent
November 17, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that it has acquired international licensing rights for IsoDermTM as well as five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects TechnologyTM, a back of the neck delivery system from its developer Dr. Ronald Aung-Din, MD. Dr. Aung-Din is a board-certified neurologist by the American Board of Psychiatry and Neurology and a recognized leader in Cannabidiol (CBD) research and its neurological benefits.
With this revolutionary non-systemic delivery system, a topical cream can be applied to the back of the neck (at the hairline) which is then picked up by the free nerve endings located in the dermis of the skin for a highly effective delivery of the compound.
“We are pleased to be moving forward with this long-anticipated transaction that gives Isodiol the international rights to the patent for specific compounds,” said Marcos Agramont, CEO of Isodiol. “We utilize the back of neck technology in our IsoDerm Direct Effects Cream where it has proven to be an extremely effective method of delivering fast relief from neurologic, psychiatric and pain conditions, without concerns of systemic side effects and drug interactions. We look forward to incorporating Dr. Aung-Din’s technologies in the development of a pipeline of products that may have significant application in the treatment of conditions that include Parkinson’s Disease, Peripheral Neuropathy, Cluster Headaches and others significant conditions. We continue to sponsor Dr. Aung-Din’s remarkable work in Autism and will continue our efforts to support the families affected by this condition.”
The Company is required to pay a one time licensing fee of $300,000 USD payable over 180 days along with continued minimum royalty payments predicated on product and territories.
$ISOLF www.isodiol.com
$ISOLF is running hard today! As far as Revenue Producing Cannabis Companies its currently ranked number #5) So its currently undervalued IMHO.
$ISOLF Pre-Market looks absolutely amazing right now
Going to be another Epic day IMHO.
Hey badog, I am a shareholder of $ACBFF and I have been for several years now.
I love this company and I truly do believe it will be nipping at Canopy's heels sooner than later.
Amazing day today on $ACBFF and $ISOLF, going to be another EPIC Day tomorrow IMHO.
Congrats to all shareholders!
I promise you, $ISOLF is literally just getting started.
This company is currently Ranked Number 5) for Revenue Producing Cannabis Companies right now.
This company has been a "Sleeping Giant" for way to long now and it looks as though $ISOLF has finally Awaken!
Look at the volume up in Canada today. Its traded over 7.8 MillioN!
This is the kicker from todays news:
""Cannabis is accepted by less than 10% of the world, while the hops plant is accepted universally," said Agramont. "This significant expansion of the global marketplace, paired with our ability to manufacture and distribute the product world-wide, gives us access to practically every country and avails this product and subsequent products to the global marketplace."
Amazing day for $ACBFF and $ISOLF so far.
$ISOLF
ISOL Announces World's 1st Hops-Derived CBD U.S Sales
ISODIOL INTERNATIONAL ANNOUNCES U.S. SALES LAUNCH OF HOPS-DERIVED CBD PRODUCT, IMMUNAG
Isodiol International Inc. has launched U.S. sales of ImmunAG, the market's first non-cnnabis cannabidiol (CBD) product derived from the hops plant. The time-released tablet will be unveiled at the Marijuana Business Conference and Expo (MJBizCon) in Las Vegas and available for purchase through Isodiol's website.
"The release of ImmunAG is a monumental milestone for Isodiol, as it marks the industry's first foray into non-cannabis CBD products," said Marcos Agramont, CEO of Isodiol. "This launch is a continuation of our company strategy to provide a diverse range of products as we strive to increase shareholder value by creating entirely new market segments."
Using proprietary extraction and purification methodologies, Isodiol is able to maintain the bioactivity (or a substances' effectiveness on a target) of the molecule at a level much greater than anything currently derived from the cannabis plant. The ImmunAG tablet does not dissolve in the stomach but rather dissolves in the lower intestine, creating greater bioactivity.
"Cannabis is accepted by less than 10% of the world, while the hops plant is accepted universally," said Agramont. "This significant expansion of the global marketplace, paired with our ability to manufacture and distribute the product world-wide, gives us access to practically every country and avails this product and subsequent products to the global marketplace."
The Company will be exhibiting all its product offerings at Booth #714 and #4699 of MJBizCon from Nov. 15-17 in Las Vegas at the Marijuana Business Conference and Expo.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
This is the week $ISOLF to finally break out IMHO. $ISOLF has too many good things going for it right now and honestly is the Diamond in the Rough right now when it comes to the Cannabis Sector.
Cheers
$IMLFF is the next $GWPH in the making! CBD is where the Cannabis sector is heading, $IMLFF is my favorite CBD Biotech company and $ISOLF is my top CBD Product Line company www.isodiol.com
Best of luck to everyone tomorrow. Cheers
Going to be another big day tomorrow for $EMHTF and $ISOLF.
My top 2 picks right now are $ACBFF and $ISOLF, going to be an epic week.
www.isodiol.com
$ISOLF www.isodiol.com
Nice to see $ISOLF volume is starting to pick up this morning.
Lets remember this is already a Revenue Producing company with a growing CBD product line and several new divisions.
Amazing day on $IMLFF, something tells me in a year from now the current share price will look very cheap IMHO.
Big Pharma could buy them out eventually.
Here's an Overview $ISOLF and $TWMJF Deal that they put together several months ago. Plus Q2 the Revenue numbers which are very impressive, when compared to their market peers. $ISOLF is the most undervalued #CBD Company in the Sector IMHO. Soon it will have its day in the sun. Patience will pay off.
VANCOUVER, /CNW/ - Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF ) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation ("Canopy") (TSX:WEED) (https://www.canopygrowth.com). ;
Canopy Growth is the world's premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company's "Pot-O-Coffee" and "Pot-O-Tea" branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and de-caffeinated product lines as well as Isodiol's single serve "Pot-O-Coco". In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the "Pot-O" brand products in any territory outside of the US, Mexico and Puerto Rico.
"This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence," stated Isodiol's CEO Marcos Agramont.
The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ISOL Q2 Below
(GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announces fiscal 2018 Q2 revenues of its wholly owned subsidiary ISO International LLC of, $4.07 million USD ($5.1 million CDN) compared to fiscal 2018 Q1 revenues of $3.92 million USD ($4.92 million CDN).
Isodiol International CEO, Marcos Agramont stated, “Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile. We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm. We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD products through innovative delivery methods, which is the core of our success.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26941181#T5HbyE5jhxPHgPUD.99
As far as a Long Term Cannabis Play $IMLFF is my favorite company in the CBD Biotech sector by a long shot.
If you are patient and can hold this stock for the next 2 to 3 years you will be rewarded in a big way.
Currently my favorite CBD Product line company which is already producing very strong revenues is $ISOLF www.isodiol.com
Both companies are in my portfolio and I truly do feel that both companies are diamonds in the rough.
$IMLFF and $ISOLF are my 2 favorites right now hands down.
Have a great night everyone. Cheers
VANCOUVER, British Columbia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce the Company’s entrance into the vaping industry by signing a Letter of Intent (“LOI”) to acquire Bradley’s Bioscience Inc., a leading manufacturer and distributer of hemp oil and nicotine e-liquids.
Bradley’s Bioscience entered the vaping market with its nicotine e-liquids, created to serve as an innovative reduced-risk product compared to traditional cigarettes. Through this agreement, the company will expand its product offerings to include non-CBD lines, hemp oil vaping e-liquids, THC additives, and organic men’s grooming products.
“The global e-cigarette and vaping market is poised to be a $61.4 billion-dollar industry by 2025, and there is a definite need for standardization in the industry,” said Marcos Agramont, CEO of Isodiol. “This acquisition gives Isodiol the ability to penetrate a new market segment, where we can continue to provide consumers with high-quality products including a safer alternative to smoking.”
Bradley’s Bioscience manufactures more than 500+ nicotine products across several brands; all of which are compliant with current FDA regulations and approved for sale in both the United States and internationally.
“Isodiol has played a pivotal role in our success over the years, by providing us and our private label consumers with the security of top tier products, supply chain consistency, a wealth of expanding knowledge and a solid support network,” said Joe Bradley, CEO of Bradley’s Bioscience. “I look forward to strengthening our brands across all industries to benefit consumers and I am confident that our products effect lives in a positive way. By partnering with Isodiol, we will be able to scale our business and grow our distribution channels across the United States and into International markets.”
For more information on Isodiol, please visit www.isodiol.com
For more information on Bradley’s Bioscience, please visit www.bradleysbrand.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
All the Licensed Producers have all had tremendous runs and now it is time for the CBD, THC Product lines to do the same.
Its going to be $ISOLF turn very soon, I feel sorry for Investors who lost their patience and sold but as Warren Buffett has state in the Past, "The stock market is an instrument to pass money from the impatient to the patient.
We will see another run before the end of the year on $ISOLF IMHO.
Here's the website for those of you who have never seen their products.
www.isodiol.com
Amazing news for $ISOLF and $WEED's Joint Venture
This is amazing news for WEED and ISOL being that they already have a joint Venture together with Pot-O-Coffee.
Also News Release (C-EAT) Nutritional High International Inc
Mr. Marcos Agramont of Isodiol reports
ISODIOL INTERNATIONAL INC. ANNOUNCES UPDATE ON COMMERCIALIZATION STRATEGY FOR POT-O-COFFEE BRAND, ACQUISITION OF CULINARY COFFEE
Isodiol International Inc. has committed distribution licences for its Pot-O-Coffee brands in the states of Oregon, Washington, Illinois and Colorado.
The Company has entered an agreement with Nutritional High (CNX:EAT), to distribute the Company's Pot-O-Coffee, Pot-O-Tea, and Pot-O-Coco product lines. The agreement will focus on specific markets in Colorado, Oregon, Washington and Illinois, in cooperation with Nutritional High's partner companies. As a part of this agreement, Nutritional High will complete the final stage of manufacturing by infusing its cannabis into the product and will provide a royalty to Isodiol.
"This strategic alliance with Nutritional High will offer our customers greater access to Pot-O-Coffee products via a reputable manufacturer and distributor," said Marcos Agramont, CEO of Isodiol. "With the recent transaction involving our Canadian licensing partner (see news release announced July 20, 2017) Canopy Growth Corporation and Constellation Brands, we feel the infused beverage industry will make significant strides in the near future."
Jim Frazier, CEO of Nutritional High commented: "We are pleased to announce the joint commercialization strategy with Isodiol. We feel that an opportunity to work with a leading international player in the space that has a track record with developing and commercializing cannabis-based consumer products. This partnership will help us expand our product reach in North America and leverage the infrastructure that we have and continue to build."
In addition to the licensing agreement, Isodiol is also pleased to announce the 100% acquisition of the assets of Culinary Coffee Roasters, LLC, a leading roaster and purveyor of fine coffee, tea and blended formulations, based in Stuart, Florida. Culinary has been in the coffee beverage business for over fifteen years. With the acquisition of this facility, the Company will be poised to launch specialty blends that will be roasted in their own facility and will be availed to mainstream retail outlets that are currently being served by Culinary. In consideration for the acquisition, Isodiol will pay $50,000 in cash over three months and $450,000 in stock equity, subject to a maximum escrow period.
"This move highlights Isodiol's focus on investing in high-growth markets and acting on consumer trends," said Agramont. "Culinary Coffee is one of the South Florida's fastest growing specialty coffee roasters and has been in the business for more than 15 years. With their industry expertise and passion for quality coffee, we will be able to further position ourselves in the recreational beverage market."
Further, Isodiol is launching its own line of handcrafted Ready to Drink (RTD) beverages in the 1st Quarter 2018. These products will include an RTD cold brew Pot-O-Coffee line as well as a cold brew Pot-O-Coffee line, all enriched with BioActive Phytoceuticals. Other offerings will include infused coffee and tea shots.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26886588#0WcLsEoHSbDacOhm.99
Amazing news for $ISOLF and $WEED's Joint Venture
This is amazing news for WEED and ISOL being that they already have a joint Venture together with Pot-O-Coffee.
Also News Release (C-EAT) Nutritional High International Inc
Mr. Marcos Agramont of Isodiol reports
ISODIOL INTERNATIONAL INC. ANNOUNCES UPDATE ON COMMERCIALIZATION STRATEGY FOR POT-O-COFFEE BRAND, ACQUISITION OF CULINARY COFFEE
Isodiol International Inc. has committed distribution licences for its Pot-O-Coffee brands in the states of Oregon, Washington, Illinois and Colorado.
The Company has entered an agreement with Nutritional High (CNX:EAT), to distribute the Company's Pot-O-Coffee, Pot-O-Tea, and Pot-O-Coco product lines. The agreement will focus on specific markets in Colorado, Oregon, Washington and Illinois, in cooperation with Nutritional High's partner companies. As a part of this agreement, Nutritional High will complete the final stage of manufacturing by infusing its cannabis into the product and will provide a royalty to Isodiol.
"This strategic alliance with Nutritional High will offer our customers greater access to Pot-O-Coffee products via a reputable manufacturer and distributor," said Marcos Agramont, CEO of Isodiol. "With the recent transaction involving our Canadian licensing partner (see news release announced July 20, 2017) Canopy Growth Corporation and Constellation Brands, we feel the infused beverage industry will make significant strides in the near future."
Jim Frazier, CEO of Nutritional High commented: "We are pleased to announce the joint commercialization strategy with Isodiol. We feel that an opportunity to work with a leading international player in the space that has a track record with developing and commercializing cannabis-based consumer products. This partnership will help us expand our product reach in North America and leverage the infrastructure that we have and continue to build."
In addition to the licensing agreement, Isodiol is also pleased to announce the 100% acquisition of the assets of Culinary Coffee Roasters, LLC, a leading roaster and purveyor of fine coffee, tea and blended formulations, based in Stuart, Florida. Culinary has been in the coffee beverage business for over fifteen years. With the acquisition of this facility, the Company will be poised to launch specialty blends that will be roasted in their own facility and will be availed to mainstream retail outlets that are currently being served by Culinary. In consideration for the acquisition, Isodiol will pay $50,000 in cash over three months and $450,000 in stock equity, subject to a maximum escrow period.
"This move highlights Isodiol's focus on investing in high-growth markets and acting on consumer trends," said Agramont. "Culinary Coffee is one of the South Florida's fastest growing specialty coffee roasters and has been in the business for more than 15 years. With their industry expertise and passion for quality coffee, we will be able to further position ourselves in the recreational beverage market."
Further, Isodiol is launching its own line of handcrafted Ready to Drink (RTD) beverages in the 1st Quarter 2018. These products will include an RTD cold brew Pot-O-Coffee line as well as a cold brew Pot-O-Coffee line, all enriched with BioActive Phytoceuticals. Other offerings will include infused coffee and tea shots.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=t.weed&postid=26886465#M2AMts7zWeXV8RDW.99
$ISOLF just needs to get more Investor attention in the States. If you go onto their website, you will see that they have several over the next few weeks here. www.isodiol.com
$ISOLF
ISODIOL INTERNATIONAL INC. PROVIDES INVESTOR UPDATE
The Canadian Securities Exchange will continue to welcome companies with links to the U.S. cannabis market, such as Isodiol International Inc., a contrast to the statement made by the TMX on Oct. 17.
Marcos Agramont, chief executive officer of Isodiol International, stated: "Our shareholders are extremely important to us, and this clarification helps alleviate any uncertainties over listings in the cannabis sector. Richard Carleton, CEO [chief executive officer] of the CNSX Markets, has publicly stated he is willing to work with and support companies in this space (1)."
The company continues to differentiate itself from other companies in the cannabis sector by developing pharmaceutical technologies that allow it to expand its global footprint and operate under legal frameworks of local governing bodies.
(1) "Marijuana stocks fall as uncertainty over listings grips the sector," The Globe and Mail, Oct. 17, 2017.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical- and nutraceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry, including commercialization of more than 99 per cent pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
This is a very positive Update from $ISOLF
ISODIOL INTERNATIONAL INC. PROVIDES INVESTOR UPDATE
The Canadian Securities Exchange will continue to welcome companies with links to the U.S. cannabis market, such as Isodiol International Inc., a contrast to the statement made by the TMX on Oct. 17.
Marcos Agramont, chief executive officer of Isodiol International, stated: "Our shareholders are extremely important to us, and this clarification helps alleviate any uncertainties over listings in the cannabis sector. Richard Carleton, CEO [chief executive officer] of the CNSX Markets, has publicly stated he is willing to work with and support companies in this space (1)."
The company continues to differentiate itself from other companies in the cannabis sector by developing pharmaceutical technologies that allow it to expand its global footprint and operate under legal frameworks of local governing bodies.
(1) "Marijuana stocks fall as uncertainty over listings grips the sector," The Globe and Mail, Oct. 17, 2017.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical- and nutraceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry, including commercialization of more than 99 per cent pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
I think this is a very smart move for $ISOLF, the fact that they are going to start utilizing Cryptocurreny as another payment method.
ISODIOL INTERNATIONAL INC. TO IMPLEMENT BLOCKCHAIN TECHNOLOGY FOR PAYMENT PROCESSING
Isodiol International Inc. is in the final stages of advanced due diligence for implementing blockchain technology for payment processing. The company has been exploring this option for several months and is working closely with an industry-specific advisory group in designing and implementing a commercialization strategy.
The Company's online sales platform has seen exponential growth since its launch and with the introduction of a digital currency payment system, Isodiol anticipates its international footprint will increase significantly. This platform will reduce processing fees incurred by the Company as well as reduce risks associated with foreign exchange fluctuations.
"There are tremendous benefits to implementing Blockchain technology and we look forward to improving our overall customer experience by providing alternative payment options," said Marcos Agramont, CEO of Isodiol International "As Blockchain technology evolves, Isodiol has every intention to continue improving its payment processing options."
The Company anticipates providing additional information on this rollout in the coming weeks.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
$ISOLF ISODIOL INTERNATIONAL INC. TO IMPLEMENT BLOCKCHAIN TECHNOLOGY FOR PAYMENT PROCESSING
Isodiol International Inc. is in the final stages of advanced due diligence for implementing blockchain technology for payment processing. The company has been exploring this option for several months and is working closely with an industry-specific advisory group in designing and implementing a commercialization strategy.
The Company's online sales platform has seen exponential growth since its launch and with the introduction of a digital currency payment system, Isodiol anticipates its international footprint will increase significantly. This platform will reduce processing fees incurred by the Company as well as reduce risks associated with foreign exchange fluctuations.
"There are tremendous benefits to implementing Blockchain technology and we look forward to improving our overall customer experience by providing alternative payment options," said Marcos Agramont, CEO of Isodiol International "As Blockchain technology evolves, Isodiol has every intention to continue improving its payment processing options."
The Company anticipates providing additional information on this rollout in the coming weeks.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
420 just tweeted this out 5 min's ago, great to get more exposure on the company. $ISOLF
Isodiol International Issues Corporate Update
2 min 32 sec ago
Isodiol International Inc.(CSE:ISOL) (OTC: $ISOLF ), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announces fiscal 2018 Q2 revenues of its wholly owned subsidiary ISO International LLC of, $4.07 million USD ($5.1 million CDN) compared to fiscal 2018 Q1 revenues of $3.92 million USD ($4.92 million CDN).
Isodiol International CEO, Marcos Agramont stated, “Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile. We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm. We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD products through innovative delivery methods, which is the core of our success.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
For sure its been a little quiet lately but I do see this changing, sooner than later if they keep putting out solid news releases and expanding the company Globally.
The fact the Anti-Doping Agency has made CBD Legal for Professional Athletes will be huge for $ISOLF.
They already have Marvin Washington, previous Superbowl Winner. I believe that he will be one of many professional athletes to come on board $ISOLF.
ISOL Q2 nearly the same as AURORA CANNABIS (ACB)
To put things in perspective for everyone, ISOL only did a $100 Grand less than ACB did this Q2.
$ACBFF is trading at $2.95 a share and they actually have WAY more Shares out than $ISOLF . Plus $ISOLF has a much lower monthly burn rate than $ACBFF .
This graph below needs to be updated being that $ISOLF should be showing a $5.1 Million Q2 but it gives you a very good understanding of where $ISOLF is heading in the near future IMHO.
Also here's this am's news for those of you who missed it.
Mr. Marcos Agramont reports
ISODIOL INTERNATIONAL PROVIDES CORPORATE UPDATE
Isodiol International Inc. has released the fiscal 2018 second quarter revenues of its wholly owned subsidiary, ISO International LLC: $4.07-million (U.S.) ($5.1-million) compared with fiscal 2018 first quarter revenues of $3.92-million (U.S.) ($4.92-million).
Isodiol International chief executive officer, Marcos Agramont, stated: "Over the last quarter, we have expanded our footprint in Brazil and more recently our operations into Chile. We will continue to push our international expansion strategy by developing the European and Asian markets for our consumer products while working with local health authorities for medical approval of our flagship product, Isoderm. We had another strong quarter of revenue growth and will continue our commitment to delivering high-quality hemp-derived CBD [cannabidiol] products through innovative delivery methods, which is the core of our success."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical- and nutraceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of plus-99-per-cent-pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.
We seek Safe Harbor.
To put things in perspective for everyone, $ISOLF only did a $100 Grand less than $ACBFF did this Q2.
ACB is trading at $2.95 a share and they actually have WAY more Shares out than ISOL. Plus ISOL has a much lower monthly burn rate than ACB.
This graph below needs to be updated being that $ISOLF should be showing a $5.1 Million Q2 but it gives you a very good understanding of where $ISOLF is heading in the near future IMHO.
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
image: https://pbs.twimg.com/media/DFvc3-mUIAImq0s.jpg:large
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.isol&postid=26808620#HdXSZjGXtMUuxGve.99
$ISOLF in the Process of Listing on the Australian Exchange.
ISODIOL INTERNATIONAL INC. COMMENCES PROCESS TO LIST ON THE AUSTRALIAN STOCK EXCHANGE
Isodiol International Inc. has initiated the process of obtaining a secondary listing on the Australian Securities Exchange and expects this process to be completed by the first quarter of 2018. The Company has successfully completed the due diligence and corporate review requirements of the exchange and will now move forward in filing for approval.
In correlation with this dual listing, the company announces a strategic investment of $1MM CDN at $.25 with a full 2-year warrant at $.75 with a 30-day acceleration clause if the stock trades above $1.00 for 10 consecutive days. This capital will be used to fund the operational expansion into Australia and certain regions of South East Asia.
Marcos Agramont, CEO of Isodiol International Inc, stated "We are excited to be expanding our footprint into Australia which we see as the gateway into Asia. We have seen incredible traction of our flagship product Isoderm{A } in Latin America and we envision similar traction in the Australasia region. Obtaining a public listing on the ASX allows us to solidify our footprint, as well as access to the capital markets that a company would not have being based in Canada. This industry is in its infancy stage in Australia and we believe we can become the leaders in innovation and product development within the region. This listing will complement our current listings on the Canadian Stock Exchange (CSE), the OTC in the US and Germany."
The Company also announces August 2017 unaudited revenue of its wholly owned subsidiary, Iso International LLC, of $1,410,743 USD. Marcos Agramont stated, "As we continue to expand our operations into international markets, maintaining strong domestic revenues in North America has been a focus for us."
The Company will provide additional information on its Australasia commercialization strategy as it is developed.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
We seek Safe Harbor.
$ISOLF is the Platinum Sponsor at the Investors Hub Conference this weekend.
https://mjac2017.com/
$ISOLF
Isodiol Is A Running Bull That Continues To See Green
13 min 54 sec ago
While Canadian licensed medical marijuana producers remain in the limelight, we have focused on several Canadian firms that are not involved in the cultivation or sale of marijuana.
We remain bullish on Canadian licensed medical marijuana producers, but believe there are several attractive long-term opportunities not focused on this side of the market.
One company that falls under this category is Isodiol International Inc. (ISOL.CN) (ISOLF) and we are bullish on its long-term growth prospects. The company continues to see significant demand for its cannabis consumer products and we are favorable on the company for the following reasons:
Continues to record strong revenue growth,
Entered a partnership with Canopy Growth (WEED.TO),
Continues to enter and focus on new international markets,
Its balance sheet is flush with cash and will support growth initiatives.
Completes $25 Million Financing
Today, Isodiol significantly strengthened its balance sheet after it signed a convertible debenture financing for $25,000,000 CDN with Alumnia Partners. The company plans to use the proceeds to further expand its global reach and to execute on strategic acquisitions. Isodiol continues to focus on innovation and the development of valuable intellectual property. This capital will support these initiatives.
The debenture has no minimum draw down requirement, a two-year term, and an 8% interest rate. The conversion terms associated with the debenture consist of one common share and one half of one common share purchase warrant at discounts ranging from 15% to 25% of the market price of the shares. The exercise price of the warrants will be at a 50% premium over the market price of the shares.
New Opportunities to Support Above-Average Growth
The last quarter has been significant for Isodiol and we expect these developments to benefit the company over the coming quarters.
In July, Canopy Growth and Isodiol signed a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it.
We are favorable on this partnership and expect it to pay dividends for Isodiol. Through Tweed Main Street, Canopy Growth services more than 58,000 registered patients and this outlet has proven to be a great revenue stream for companies such as Isodiol.
Continues to Increase Market Share and Enter New Markets
Isodiol continues to expand its reach and has successfully entered new markets. We are favorable on these developments and expect the company to enter several new markets over the next year.
One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.
We are favorable on the Brazil market and believe that the company can gain significant traction within it. Shortly after this announcement, Isodiol reported to have established operations in Mexico and said that it would start shipping its CBD products throughout the country.
Executing on All Cylinders
Last month, Isodiol provided an operational update on its subsidiary, Iso International and the results exceeded our expectations. During the period, Iso recorded a net profit of almost $897,596 on $4,919,693 in revenue. Although these numbers are un-audited, we expect the company to report operating results that are in line with these numbers.
This development is significant for Isodiol and represents a milestone for the company. Isodiol has continued to execute on its business plan and specializes in the development of pharmaceutical and consumer products.
We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for quarters to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.